BE705317A - - Google Patents
Info
- Publication number
- BE705317A BE705317A BE705317DA BE705317A BE 705317 A BE705317 A BE 705317A BE 705317D A BE705317D A BE 705317DA BE 705317 A BE705317 A BE 705317A
- Authority
- BE
- Belgium
- Prior art keywords
- streptomycin
- oxidation products
- terpine
- antibiotic
- hydrate
- Prior art date
Links
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical class CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 33
- 230000003647 oxidation Effects 0.000 description 19
- 238000007254 oxidation reaction Methods 0.000 description 19
- 239000000047 product Substances 0.000 description 19
- 229960005322 streptomycin Drugs 0.000 description 16
- JGKJMBOJWVAMIJ-UHFFFAOYSA-N 4-(2-hydroxypropan-2-yl)-1-methylcyclohexan-1-ol;hydrate Chemical compound O.CC(C)(O)C1CCC(C)(O)CC1 JGKJMBOJWVAMIJ-UHFFFAOYSA-N 0.000 description 15
- 239000003242 anti bacterial agent Substances 0.000 description 14
- RBNWAMSGVWEHFP-UHFFFAOYSA-N cis-p-Menthan-1,8-diol Natural products CC(C)(O)C1CCC(C)(O)CC1 RBNWAMSGVWEHFP-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000003115 biocidal effect Effects 0.000 description 13
- 229940088710 antibiotic agent Drugs 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 235000007586 terpenes Nutrition 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000012458 free base Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- -1 @ihydrostreptsmycin Chemical compound 0.000 description 5
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229960002222 dihydrostreptomycin Drugs 0.000 description 5
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 4
- 241000779819 Syncarpia glomulifera Species 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 239000001739 pinus spp. Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229960002385 streptomycin sulfate Drugs 0.000 description 4
- 150000003505 terpenes Chemical class 0.000 description 4
- 229940036248 turpentine Drugs 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- OZKXLOZHHUHGNV-UHFFFAOYSA-N Viomycin Natural products NCCCC(N)CC(=O)NC1CNC(=O)C(=CNC(=O)N)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC1=O)C2CC(O)NC(=N)N2 OZKXLOZHHUHGNV-UHFFFAOYSA-N 0.000 description 2
- 108010015940 Viomycin Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229940035024 thioglycerol Drugs 0.000 description 2
- 229950001272 viomycin Drugs 0.000 description 2
- GXFAIFRPOKBQRV-GHXCTMGLSA-N viomycin Chemical compound N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)C[C@@H](N)CCCN)CNC(=O)[C@@H]1[C@@H]1NC(=N)N[C@@H](O)C1 GXFAIFRPOKBQRV-GHXCTMGLSA-N 0.000 description 2
- YXIORFGPXSLCOT-FGZKHVCBSA-N 2-[(1r,2r,3s,4r,5r,6s)-3-(diaminomethylideneamino)-4-[(2r,3r,4r,5s)-3-[(2s,3s,4s,5r,6s)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy-2,5,6-trihydroxycyclohexyl]guanidine;3-[[(2r)-2,4-dihydroxy-3,3 Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O.O1[C@@H](CO)[C@H](O)[C@@H](O)[C@H](NC)[C@@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O YXIORFGPXSLCOT-FGZKHVCBSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000764868 Oodes Species 0.000 description 1
- 206010033109 Ototoxicity Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- ISXSFOPKZQZDAO-UHFFFAOYSA-N formaldehyde;sodium Chemical compound [Na].O=C ISXSFOPKZQZDAO-UHFFFAOYSA-N 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000262 ototoxicity Toxicity 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 229940041022 streptomycins Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEC0040442 | 1966-01-19 | ||
| DEC0040443 | 1966-10-19 | ||
| DEC0040441 | 1966-10-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE705317A true BE705317A (enrdf_load_html_response) | 1968-03-01 |
Family
ID=27209620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE705317D BE705317A (enrdf_load_html_response) | 1966-01-19 | 1967-10-18 |
Country Status (2)
| Country | Link |
|---|---|
| BE (1) | BE705317A (enrdf_load_html_response) |
| FR (1) | FR8387M (enrdf_load_html_response) |
-
1967
- 1967-10-18 BE BE705317D patent/BE705317A/fr unknown
-
1968
- 1968-01-18 FR FR125138A patent/FR8387M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| FR8387M (enrdf_load_html_response) | 1971-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR860001503B1 (ko) | 이버멕틴의 수용화 방법 | |
| CH651208A5 (fr) | Composition pharmaceutique aqueuse diluee stabilisee pour l'administration du 1alpha,25-dihydroxycholecalciferol a des nouveaux-nes. | |
| FR2472388A1 (fr) | Compositions pharmaceutiques contenant un produit corticosteroide | |
| FR2914188A1 (fr) | Nouvelle composition a base d'oxime de cholest-4-en-3-one | |
| BE895724A (fr) | Nouvelle utilisation therapeutique de la dihydrocyclosporine d | |
| SU1277943A1 (ru) | Зоотехнический состав | |
| FR2480603A1 (fr) | Composition pharmaceutique pour administration par voie orale contenant de la cytidine-diphosphocholine | |
| FR2584405A1 (fr) | Sels de furosemide, composition pharmaceutique les contenant et leur procede de preparation | |
| FR2505184A1 (fr) | Procede de prevention de la paralysie vitulaire chez la vache laitiere | |
| US4128632A (en) | Solubilization of Rafoxanide | |
| CH642544A5 (fr) | Composition pharmaceutique d'erythromycine. | |
| CH644015A5 (fr) | Solution aqueuse injectable a base d'oxytetracycline. | |
| BE705317A (enrdf_load_html_response) | ||
| US4322401A (en) | Permanent-wave solution | |
| BE1004051A4 (fr) | Solution injectable et procede pour la preparer. | |
| EP0920320A2 (fr) | Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol | |
| FR2561522A1 (fr) | Solution injectable, notamment pour le traitement de la cetose et son procede de preparation | |
| EP0069674A1 (fr) | Médicaments contenant une N-acyl-L-aspartyl-taurine | |
| EP0575481B1 (fr) | Nouvelles compositions liquides a base de derives de la piperidine substitues en 1,4 | |
| FR2485371A1 (fr) | Nouvelle composition a usage therapeutique a base de lysine et d'arginine | |
| EP0271374B1 (fr) | Composition antibiotique aqueuse à usage vétérinaire | |
| EP0520865A1 (fr) | Utilisation de dérivés d'acide pour la fabrication d'un médicament pédiculicide | |
| BE897980A (fr) | Procede pour la preparation d'une solution a usage pharmaceutique contenant un nouveau complexe mixte polynuclaire de fer (iii) comme ingredient actif | |
| FR2517542A1 (fr) | Medicament pour l'amelioration du metabolisme lipidique | |
| RU2045266C1 (ru) | Вещество, проявляющее желчегонное действие |